IPHA · Innate Pharma S.A.
AI read · Bad for IPHA
The AI's read
This suggests the analyst sees less promise in Innate Pharma's shares after its early study update. Earlier coverage pointed to tumor-fighting activity and stable linkers, but the new downgrade is the clearest signal and weighs against the company.